BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26132201)

  • 1. Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.
    Lawrenson K; Pakzamir E; Liu B; Lee JM; Delgado MK; Duncan K; Gayther SA; Liu S; Roman L; Mhawech-Fauceglia P
    PLoS One; 2015; 10(7):e0130909. PubMed ID: 26132201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
    PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
    Ramalingam P; Masand RP; Euscher ED; Malpica A
    Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.
    Jones NL; Xiu J; Chatterjee-Paer S; Buckley de Meritens A; Burke WM; Tergas AI; Wright JD; Hou JY
    Int J Cancer; 2017 Mar; 140(6):1396-1404. PubMed ID: 27905110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma.
    Mhawech-Fauceglia P; Walia S; Yessaian A; Machida H; Matsuo K; Lawrenson K
    Pathology; 2018 Aug; 50(5):499-503. PubMed ID: 29891190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
    Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
    Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
    Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
    Strehl JD; Wachter DL; Fiedler J; Heimerl E; Beckmann MW; Hartmann A; Agaimy A
    Ann Diagn Pathol; 2015 Aug; 19(4):198-202. PubMed ID: 25920939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
    Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
    Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
    Schlosshauer PW; Ellenson LH; Soslow RA
    Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus.
    Ervine A; Leung S; Gilks CB; McCluggage WG
    Histopathology; 2014 May; 64(6):840-6. PubMed ID: 24267480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Herrmann FR; Rai H; Tchabo N; Lele S; Izevbaye I; Odunsi K; Cheney RT
    Am J Clin Pathol; 2010 Jun; 133(6):899-908. PubMed ID: 20472848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
    An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
    Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.